Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib First-Line in GIST
NCT00568750Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jan 2008
- Primary completion
- Jan 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of dasatinib in gastrointestinal stromal tumor (GIST), sponsored by Swiss Group for Clinical Cancer Research. Started Jan 2008; status: completed.
02
Drugs
dasatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00568750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00568750.